Background: Decreased bone mineral density (BMD) has been associated with the use of tenofovir disoproxil fumarate (TDF) in HIV-infected adults. The data in HIV-infected children are conflicting. The aim of this study was to assess the safety of a TDF-containing antiretroviral (ARV) regimen on BMD in paediatric patients. We report the results of a longitudinal 60-month follow-up study. Methods: A total of 21 vertically HIV-infected Caucasian youths (10 male and 11 female) on ARV treatment containing lamivudine, efavirenz and TDF were enrolled (age range 4.9-17.9 years at baseline). BMD was measured at the lumbar spine and in the whole skeleton by DXA. Bone-specific alkaline phosphatase (BAP) was measured as a bone formation marker and urinary N-telopeptide of type-I collagen (NTx) was measured as a bone resorption index. Results: Baseline mean (+/-SD) BMD measurements of HIV-infected patients expressed as z-scores were -0.7 (+/-0.9) for lumbar spine and -0.13 (+/-1.0) for the whole skeleton. BMD measurements did not change significantly during the 60-month observation period. Both BAP and NTx concentrations were higher than a reference group of controls at baseline and remained unchanged throughout the study. Conclusions: Our data indicate that a TDF-containing regimen does not decrease the BMD of HIV-infected youths.
Tenofovir disoproxil fumarate and bone mineral density : a 60-month longitudinal study in a cohort of HIV-infected youths / A. Viganò, G.V. Zuccotti, M. Puzzovio, V. Pivetti, I. Zamproni, C. Cerini, V. Fabiano, V. Giacomet, S. Mora. - In: ANTIVIRAL THERAPY. - ISSN 1359-6535. - 15:7(2010), pp. 1053-1058. [10.3851/IMP1650]
Tenofovir disoproxil fumarate and bone mineral density : a 60-month longitudinal study in a cohort of HIV-infected youths
G.V. Zuccotti;V. Pivetti;C. Cerini;V. Fabiano;V. Giacomet;
2010
Abstract
Background: Decreased bone mineral density (BMD) has been associated with the use of tenofovir disoproxil fumarate (TDF) in HIV-infected adults. The data in HIV-infected children are conflicting. The aim of this study was to assess the safety of a TDF-containing antiretroviral (ARV) regimen on BMD in paediatric patients. We report the results of a longitudinal 60-month follow-up study. Methods: A total of 21 vertically HIV-infected Caucasian youths (10 male and 11 female) on ARV treatment containing lamivudine, efavirenz and TDF were enrolled (age range 4.9-17.9 years at baseline). BMD was measured at the lumbar spine and in the whole skeleton by DXA. Bone-specific alkaline phosphatase (BAP) was measured as a bone formation marker and urinary N-telopeptide of type-I collagen (NTx) was measured as a bone resorption index. Results: Baseline mean (+/-SD) BMD measurements of HIV-infected patients expressed as z-scores were -0.7 (+/-0.9) for lumbar spine and -0.13 (+/-1.0) for the whole skeleton. BMD measurements did not change significantly during the 60-month observation period. Both BAP and NTx concentrations were higher than a reference group of controls at baseline and remained unchanged throughout the study. Conclusions: Our data indicate that a TDF-containing regimen does not decrease the BMD of HIV-infected youths.File | Dimensione | Formato | |
---|---|---|---|
Antivir Ther (Lond)-2010-Viganò.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
143.44 kB
Formato
Adobe PDF
|
143.44 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.